Company: ADPT
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000950170-25-061897
Chunk: 1

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-05-01
Form: 10-Q
Item: Item 1
Chunk 1
---
 current portion

     76,438

     79,148

     Deferred revenue, less current portion

     24,814

     27,256

     Revenue interest liability, net, less current portion

     131,550

     132,414

     Other long-term liabilities

     20

     20

     Total liabilities

     320,631

     336,891

     Commitments and contingencies (Note 9)

     Shareholders’ equity

     Preferred stock: $0.0001 par value, 10,000,000 shares authorized at March 31, 2025 and December 31, 2024; no shares issued and outstanding at March 31, 2025 and December 31, 2024

     —

     —

     Common stock: $0.0001 par value, 340,000,000 shares authorized at March 31, 2025 and December 31, 2024; 151,916,722 and 147,773,744 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively

     15

     14

     Additional paid-in capital

     1,523,950

     1,506,353

     Accumulated other comprehensive gain

     134

     166

     Accumulated deficit

     (1,333,676
     )

     (1,303,824
     )

     Total Adaptive Biotechnologies Corporation shareholders’ equity

     190,423

     202,709

     Noncontrolling interest

     (202
     )

     (224
     )

     Total shareholders’ equity

     190,221

     202,485

     Total liabilities and shareholders’ equity
      
     $
     510,852

     $
     539,376

The accompanying notes are an integral part of these condensed consolidated financial statements.